Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: OSI Pharmaceuticals, Inc
Woman and Man Max 99 years
OSI Pharmaceuticals, Inc
Update Il y a 4 ans
A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumors with EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers
Evaluate in parallel the efficacy of 2 different Tarceva-containing regimens as first-line therapy measured as the percentage of patients that have progressed at 6 months among stage IIIB/IV NSCLC pat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
OSI Pharmaceuticals, Inc
Update Il y a 4 ans
A Randomized, Open Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract
To determine the objective response rates in patients with untreated unresectable, locally advanced or metastatic cancer of the biliary tract who are treated with OSI-7904L or 5-FU/LV.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
OSI Pharmaceuticals, Inc
Update Il y a 4 ans
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors. Estudio fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de una monoterapia con Tarceva® (erlotinib) tras una resección tumoral completa, con o sin quimioterapia adyuvante, en pacientes con cáncer de pulmón de células no pequeñas en estadios IB-IIIA que tienen tumores EGFR-positivo
The primary objectives of this study are to assess the efficacy of single agent, oral, once daily, Tarceva (150 mg/day) at increasing the DFS following complete surgical resection with or without adju...
Country
None
organs
None
Specialty
None
Closed trial
More information